Cervical Neuroendocrine Carcinoma: A Rare Case Report

Tarun Kumar¹, Jitendra S. Nigam¹, Madhu Kumari¹, Swati¹, Jagjit Pandey²

1. Pathology/Lab Medicine, All India Institute of Medical Sciences, Patna, IND 2. Surgical Oncology, All India Institute of Medical Sciences, Patna, IND

Corresponding author: Tarun Kumar, drtarunk@aiimspatna.org

Abstract

Neuroendocrine carcinoma is a rare tumor in the uterine cervix with a dismal prognosis. Clinically, it is difficult to differentiate from other cervical malignancies. Clinical presentation varies from vaginal bleeding, discharge per vaginam and cervical mass. For better clinical outcomes, it is vital to diagnose promptly and accurately. We report a 35-year-old female presented with whitish discharge per vaginam and lower abdominal pain for six months. Per speculum reveals an irregular, firm mass measuring 4x3 cm involving both the cervical lips, which turned out to a small cell neuroendocrine carcinoma.

Categories: Obstetrics/Gynecology, Pathology

Keywords: cervix, neuroendocrine, pap smear, carcinoma, small cell

Introduction

Cervix cancer is the second most common cancer constituting 22.86% of all cancer cases in Indian women [1]. Neuroendocrine (NE) neoplasms (NENs) are NE cell-derived malignancies that can occur in various parts of the body, including the female genital tract [2]. NENs of the cervix are uncommon, divided into NE tumors (NETs) and NE carcinomas (NECs) [3]. Both NETs and NECs have a similar clinical presentation, such as vaginal bleeding, discharge, and cervical mass, as seen in other cervical malignancies but have variable prognoses [4]. NETs constitute low-grade epithelial neoplasm (Grade 1 and Grade 2) [3]. Small cell NE carcinoma (SCNEC) and large cell NE carcinoma (LCNEC) are included in high-grade carcinoma [3]. Therefore, early and correct diagnosis is of utmost importance because of its aggressive behavior, dismal prognosis, and specific treatment modalities [5]. Herein we are presenting this case due to its rarity in a young female having a diagnostic pitfall.

Case Presentation

A 35-year-old female presented to the gynecology outpatient department with a complaint of whitish discharge per vaginam and lower abdominal pain for six months. The menstrual history was unremarkable. Per speculum reveal an irregular, firm mass measuring 4x3 cm involving both the lips of the cervix. Clinical suspicion of carcinoma cervix, International Federation of Gynaecology and Obstetrics (FIGO) stage 2A was made. Pap smear reveals a cellular smear showing atypical cells arranged in a small cluster and few singly scattered, having increased nuclear-cytoplasmic ratio, scant cytoplasm, and coarse to hyperchromatic nuclei. Pseudo-rosette-like glandular differentiation and occasional nuclear molding are also noted (Figures 1A-1D).

Review began 05/24/2021

Review ended 06/08/2021

Published 06/08/2021

© Copyright 2021

Kumar et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

How to cite this article

Kumar T, Nigam J S, Kumari M, et al. (June 08, 2021) Cervical Neuroendocrine Carcinoma: A Rare Case Report. Cureus 13(6): e15532. DOI 10.7759/cureus.15532

FIGURE 1: Cervical Pap Smear Cytology Examination

(A) Clusters of atypical cells (Papanicolaou stain, x100). (B) Malignant cells with high nuclear-cytoplasmic ratio and hyperchromatic nuclei in a necrotic background (Papanicolaou stain, x400). (C) Malignant cells displaying nuclear molding (Papanicolaou stain, x400). (D) Occasional acinar arrangement (Papanicolaou stain, x400).

The background shows necrosis and acute inflammatory cells. A cytological diagnosis of atypical - glandular cells, favor neoplastic was suggested. Whole-body F-18 labeled fluorodeoxyglucose (FDG)-positron emission tomography (PET) scan reveals an active hypermetabolic soft tissue thickening in the cervix. The left inguinal, pelvic, and mesenteric lymph nodes showed metastatic evidence (Figure 2).

FIGURE 2: Whole-Body Fluorodeoxyglucose F-18 Positron Emission Tomography Scan

Active hypermetabolic soft tissue thickening in the cervix with left inguinal, pelvic, and mesenteric lymph node metastasis.

Biopsy from the lesion shows tumor cells arranged in the nest, lobule, and diffuse pattern. The tumor is composed of monomorphic, round to oval cells. These cells were having a high nuclear-cytoplasmic ratio, hyperchromatic nuclei, inconspicuous nucleoli, and scant cytoplasm. Few cells showed stippled chromatin and nuclear molding. Occasional atypical mitosis and focal crushing artifact are also noted (Figures 3A-3D).

FIGURE 3: Hematoxylin and Eosin-Stained Sections From Cervical Tissue

(A) Tumor with cervical epithelial ulceration (H&E, x20). (B, C) Stroma infiltrated by tumor cells arranged in diffuse sheets and vague nested pattern (H&E, x40, x100). (D) Monomorphic, small to round tumor cells having hyperchromatic nuclei, high nuclear-cytoplasmic ratio, and scant cytoplasm. Atypical mitosis is also noted (arrow) (H&E, x400).

H&E - Hematoxylin and eosin

The tumor cells are immunopositive for synaptophysin, chromogranin, and non-specific enolase (NSE). The Ki-67 labeling index was more than 90% (Figures 4A-4D).

FIGURE 4: Immunohistochemistry

(A) Tumor cells are immunopositive for synaptophysin (x100). (B) Tumor cells are immunopositive for chromogranin (x100). (C) Tumor cells are immunopositive for non-specific enolase (x40). (D) Tumor area shows high Ki 67 proliferating index (x40).

We rendered the final histopathological diagnosis of high-grade NE carcinoma, small cell type, cervix. Based on the clinico-radiological assessment and tumor board decision, three cycles of neoadjuvant chemotherapy (carboplatin + etoposide) were given, followed by chemoradiotherapy. After completion of chemoradiotherapy, the patient was lost to follow up.

Discussion

NENs of the cervix were first described by Albores-Saavedra et al. in 1972 [6]. The exact origin of the NENs of the cervix is unknown [7]. However, argyrophilic cells in ectocervix and endocervix epithelium are considered a potential precursor for NENs [7]. Among NENs of the cervix, SCNEC is the most common (80%) variant, and it constitutes <1% of all female genital tract malignancies [8,9]. The mean age of SCNEC diagnosis is 48.1 years [9]. NECs are more prone to early lymphatic and hematogenous spread and increased risk of nodal metastases even when the tumor is clinically limited to the cervix [8].

Diagnostic accuracy in detecting SCNECs by Pap smear is very low [10]. However, Pap smear shows singly and loosely cohesive groups of relatively uniform small cells [11]. These cells have hyperchromatic nuclei with granular or stippled chromatin, inconspicuous nucleoli, and scant cyanophilic cytoplasm [11]. Nuclear molding, crush artifacts, necrosis, and mitotic figures are also identified [11]. In our case, the patient was middle-aged, and her cervical Pap smear did not reveal any definitive features of NENs.

Histomorphology includes various differential diagnoses such as poorly differentiated squamous carcinoma with small cells, poorly differentiated adenocarcinoma, low-grade endometrial stromal sarcoma, lymphoma, rhabdomyosarcoma, melanoma, myeloid sarcoma, and primitive neuroectodermal tumor (PNET) [11]. McCluggage et al. found that synaptophysin and CD56 are the most sensitive, while chromogranin is the most specific NE immunohistochemical marker [12]. Based on histomorphology and IHC, we exclude all the differential diagnoses in our index case.

NECs are spread by lymphatic and hematogenous routes even if the tumor is clinically confined to the cervix [8]. The tumor was localized to the cervix in the present case, with multiple lymph node metastases. The 2018 FIGO staging system incorporates imaging such as computed tomography (CT) or PET/CT scan and pathologic findings for tumor staging [13,14].

Castle et al. found that 85% of SCNEC and 88% of LCNEC of the cervix were human papillomavirus (HPV) positive. They also conclude that these tumors may be prevented by the use of prophylactic HPV vaccines [15].

Treatment of NETs of the cervix is a multimodality approach [8]. For early-stage disease, radical hysterectomy is followed by adjuvant concurrent chemoradiation and chemotherapy. The use of the immune checkpoint inhibitor (Nivolumab) with or without stereotactic body radiation therapy (SBRT) is helpful in the management of NECs of the cervix [16,17]. Lyons et al. claim successful treatment of recurrent SCNEC of the cervix by the use of trametinib, a MEK inhibitor [18].

Locally advanced disease by concurrent chemoradiation and chemotherapy and palliative chemotherapy for the metastatic tumor is recommended [8]. Since our case was clinically FIGO stage IIA, three cycles of concurrent chemoradiation followed by chemotherapy were administered. The tumor stage is the most critical poor prognostic factor and other independent prognostic factors such as age, tumor size, lymph node metastases, and pure small cell histology [8].

In the index case, poor prognostic factors were tumor stage, lymph node metastasis, and pure small cell histology. Overall, the prognosis remains poor despite multimodal treatment strategy, with a five-year survival rate of 36% and a median overall survival between 22 and 25 months [8].

Conclusions

SCNECs of the cervix are rare with an aggressive clinical course. Since cervical Pap smear is routine screening processing worldwide, pseudo-rosette-like differentiation and nuclear molding are the important cytological findings that may be considered for suspicion of NE tumors by cytopathologists as observed in our case. It is of utmost importance to accurately diagnose and differentiate from the other high-grade cervical carcinoma for better clinical management.

Additional Information

Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Cancer Statistics. (2021). Accessed: May 24, 2021: <http://cancerindia.org.in/cancer-statistics/>.
2. Tempfer CB, Tischoff I, Dogan A, Hilal Z, Schultheis B, Kern P, Reznicek GA: Neuroendocrine carcinoma of the cervix: a systematic review of the literature. *BMC Cancer*. 2018, 18:530. [10.1186/s12885-018-4447-x](https://doi.org/10.1186/s12885-018-4447-x)
3. McCluggage WG: Neuroendocrine neoplasia: introduction. *WHO Classification of Tumours*. Cree IA, Malpica A, McCluggage WG (ed): IARC, Lyon; 2020. 5th edition:452.
4. Colgan TJ, Hirschowitz L, Kim I, et al.: Neuroendocrine tumours. *WHO Classification of Tumours of Female Reproductive Organs*. Kurman RJ, Carcangiu ML, Herrington CS, et al. (ed): IARC, Lyon; 2014. 4th Edition:196-8.
5. Li S, Zhu H: Twelve cases of neuroendocrine carcinomas of the uterine cervix: cytology, histopathology and discussion of their histogenesis. *Acta Cytol*. 2013, 57:54-60. [10.1159/000342516](https://doi.org/10.1159/000342516)
6. Albores-Saavedra J, Larraza O, Poucell S, et al.: Carcinoid of the uterine cervix: additional observations on a new tumor entity. *Cancer*. 1976, 38:2328-42. [10.1002/1097-0142\(197612\)38:6<2328::AID-CNCR2820380620>3.0.CO;2-J](https://doi.org/10.1002/1097-0142(197612)38:6<2328::AID-CNCR2820380620>3.0.CO;2-J)
7. Pirog EC, Wright TC, Ronnett BM, et al.: Carcinoma and other tumors of the cervix. *Blaustein's Pathology of the Female Genital Tract*. Kurman RJ, Ellenson LH, Ronnett BM (ed): Springer Nature, Switzerland; 2019. 7th edition:364.
8. Salvo G, Gonzalez Martin A, Gonzales NR, Frumovitz M: Updates and management algorithm for neuroendocrine tumors of the uterine cervix. *Int J Gynecol Cancer*. 2019, 29:986-95. [10.1136/ijgc-2019-000504](https://doi.org/10.1136/ijgc-2019-000504)
9. Alvarad-Cabrero I, Euscher ED, Ganesan R, et al.: Small cell neuroendocrine carcinoma. *WHO Classification of Tumours Female Genital Tumours*. Cree IA, Malpica A, McCluggage WG (ed): IARC, Lyon; 2020. 5th edition:455-6.
10. Park HJ, Choi YM, Chung CK, et al.: Pap smear screening for small cell carcinoma of the uterine cervix: a case series and review of the literature. *J Gynecol Oncol*. 2011, 22:39-43. [10.3802/jgo.2011.22.1.39](https://doi.org/10.3802/jgo.2011.22.1.39)
11. Tabbara SO, Khalbuss WE: Other malignant neoplasms. *The Bethesda System for Reporting Cervical Cytology*. Nayar R, Wilbur DC (ed): Springer, Switzerland; 2015. 3rd edition:244-6.
12. McCluggage WG, Kennedy K, Busam KJ: An immunohistochemical study of cervical neuroendocrine carcinomas: neoplasms that are commonly TTF1 positive and which may express CK20 and P63. *Am J Surg Pathol*. 2010, 34:525-32. [10.1097/PAS.0b013e3181d1d457](https://doi.org/10.1097/PAS.0b013e3181d1d457)
13. Bhatla N, Aoki D, Sharma DN, Sankaranarayanan R: Cancer of the cervix uteri. *Int J Gynaecol Obstet*. 2018, 143 Suppl 2:22-36. [10.1002/ijgo.12611](https://doi.org/10.1002/ijgo.12611)
14. Gardner GJ, Reidy-Lagunes D, Gehrig PA: Neuroendocrine tumors of the gynecologic tract: a Society of Gynecologic Oncology (SGO) clinical document. *Gynecol Oncol*. 2011, 122:190-8. [10.1016/j.ygyno.2011.04.011](https://doi.org/10.1016/j.ygyno.2011.04.011)

15. Castle PE, Pierz A, Stoler MH: A systematic review and meta-analysis on the attribution of human papillomavirus (HPV) in neuroendocrine cancers of the cervix. *Gynecol Oncol*. 2018, 148:422-9. [10.1016/j.ygyno.2017.12.001](https://doi.org/10.1016/j.ygyno.2017.12.001)
16. Sharabi A, Kim SS, Kato S, et al.: Exceptional response to nivolumab and stereotactic body Radiation therapy (SBRT) in neuroendocrine cervical carcinoma with high tumor mutational burden: management considerations from the Center For Personalized Cancer Therapy at UC San Diego Moores Cancer Center. *Oncologist*. 2017, 22:631-7. [10.1634/theoncologist.2016-0517](https://doi.org/10.1634/theoncologist.2016-0517)
17. Paraghamian SE, Longoria TC, Eskander RN: Metastatic small cell neuroendocrine carcinoma of the cervix treated with the PD-1 inhibitor, nivolumab: a case report. *Gynecol Oncol Res Pract*. 2017, 4:3. [10.1186/s40661-017-0038-9](https://doi.org/10.1186/s40661-017-0038-9)
18. Lyons YA, Frumovitz M, Soliman PT: Response to MEK inhibitor in small cell neuroendocrine carcinoma of the cervix with a KRAS mutation. *Gynecol Oncol Rep*. 2014, 10:28-9. [10.1016/j.gore.2014.09.003](https://doi.org/10.1016/j.gore.2014.09.003)